Within the limits imposed by the relatively small cohort here reported, our data suggest that SSTR2-IHC may surrogate SSTR-PET/CT in selected lung NET patients for effective clinical decision making when SSTR-PET/CT is not available or where financial constraints limits the access to in vivo SSTR assessment. This evidence concerns the gene SSTR2 and lung neuroendocrine neoplasm.